FDA names Pazdur as CDER director Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 12 November, 2025

Our latest survey captured the bleakest biotech outlook in a decade — but is recent momentum real or a mirage? Join us to hear what CEOs are saying about the industry’s direction. Sign up now.

presented by Da­ta Built for Dis­cov­ery: Ad­vanc­ing Pre­ci­sion Med­i­cine Through In­ten­tion­al De­sign

news FDA taps Richard Pazdur as new CDER director after Tidmarsh's resignation Bayer’s pharma division makes some strides as restructuring continues Exclusive: Ovid co-founder and CEO Levin plans leadership handoff in 2026

Nov 12 2:30pm ET From JP Morgan to the next wave: What's driving biotech in 2026 sponsored by Precision AQ Nov 13 11:00am ET Driving down the cost: Optimising CGT with the right CDMO partner sponsored by OXB Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine

Clinical trials are slower and costlier than ever — yet the pressure to move fast has never been higher. Join Endpoints News for a conversation on what’s shifting, what’s working, and where the industry goes next. Sign up today.

in case you missed it 1. Regeneron, CRISPR Therapeutics execs will represent biotech at Wednesday MAHA event 2. Why class competition hasn't brought checkpoint inhibitor prices down 3. CDMOs don’t expect immediate impact from ‘most favored nation’ deals 4. KalVista defies sales expectations again for hereditary angioedema drug 5. News Briefing Voyager, Transition Bio's small molecule drug pact; CRISPR Therapeutics ends work on a CAR-T therapy 6. How Hinge Health pulled off its IPO 7. Nine takeaways from our first-ever Health Tech Day 8. EnGene posts more pivotal data for bladder cancer gene therapy, plans 2026 filing 9. Neurocrine reports Phase 2 fail for depression drug it licensed from Takeda 10. China’s new scientist visa is a ‘serious bid’ for the world’s top talent